United States Nanotechnology in Drug Delivery Market 2026 | Growth Drivers, Trends & Market Forecast, Competitive Landscape & Investment Opportunities

Market Size and Growth

Nanotechnology in Drug Delivery Market size was valued at US$ 51.4 billion in 2023 and is estimated to reach US$ 203.6 billion by 2030, growing at a CAGR of 17.9% during the forecast period (2024-2031)

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/nanotechnology-in-drug-delivery-market?sb

Key Development:

United States: Recent Industry Developments

✅ In March 2026, Moderna announced continued investment in lipid nanoparticle delivery platforms to enhance targeted mRNA drug delivery for oncology and rare disease therapies. The research focuses on improving stability and tissue-specific delivery of genetic medicines. The development strengthens next-generation nanotechnology-based therapeutics in the United States.

✅ In February 2026, Pfizer expanded its collaboration with academic research institutes to develop nanoparticle-based drug delivery systems for precision cancer treatment. The program focuses on improving drug targeting and reducing systemic toxicity. It supports the advancement of nanomedicine for personalized healthcare applications.

✅ In January 2026, Johnson & Johnson launched a new research initiative on nanocarrier drug delivery technologies designed to improve controlled release and bioavailability of complex therapeutics. The platform integrates polymeric nanoparticles and liposomal systems. It aims to enhance treatment efficiency in chronic and infectious diseases.

✅ In December 2025, the U.S. FDA granted approval for a nanoparticle-based formulation of an anticancer drug designed to improve targeted delivery and reduce side effects. The formulation uses advanced nano-encapsulation technology for controlled drug release. The approval highlights growing regulatory acceptance of nanotechnology in pharmaceutical applications.

Request Updated Sample: https://www.datamintelligence.com/download-sample/updated/nanotechnology-in-drug-delivery-market?sb

Japan: Recent Industry Developments

✅ In March 2026, Takeda Pharmaceutical announced new R&D investment in nanotechnology-based drug delivery platforms to improve targeted therapy for gastrointestinal and rare diseases. The research focuses on biodegradable nanoparticles for controlled drug release. It supports Japan's innovation in advanced pharmaceutical technologies.

✅ In February 2026, Daiichi Sankyo launched a development program using nano-carrier systems to enhance delivery of antibody-drug conjugates for cancer treatment. The technology improves drug stability and precision targeting. It strengthens Japan's position in next-generation oncology therapeutics.

✅ In January 2026, Astellas Pharma initiated research on lipid nanoparticle delivery systems for gene therapy and RNA-based medicines. The program aims to improve cellular uptake and therapeutic efficiency. It expands Japan's capabilities in nanomedicine and advanced drug delivery solutions.

✅ In December 2025, Eisai announced collaboration with a Japanese nanotechnology research institute to develop nano-formulated drugs for neurological disorders. The project focuses on crossing the blood-brain barrier using engineered nanoparticles. It supports innovation in treatments for Alzheimer's and other CNS diseases.

Key Players:

=> Ceramisphere Health Pvt Limited, Cristal Therapeutics, CYTIMMUNE SCIENCES, Inc., Nanobiotix, NanoCarrier Co. Ltd., NanOlogy LLC, EnColl Corporation, EyePoint Pharmaceuticals, AbbVie Inc., Aquanova AG, BlueWillow Biologics, Camurus AB, Celgene, Inc., Lena Nanoceutics Ltd.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/nanotechnology-in-drug-delivery-market?sb

Key Segments:

By Technology

Nanoparticles dominate with 30% share, driven by their extensive use in targeted drug delivery, improved bioavailability, and controlled release of therapeutic agents. Liposomes account for 25%, supported by their strong adoption in cancer therapy and vaccine delivery due to high biocompatibility and ability to carry both hydrophilic and hydrophobic drugs. Micelles for Nanotechnology in Drug Delivery hold 18%, fueled by increasing use in solubility enhancement and precision drug delivery applications. Nanocrystals represent 15%, driven by their effectiveness in improving drug dissolution and absorption. Others contribute 12%, including dendrimers and nanoemulsions used in specialized pharmaceutical applications.

By Applications

Oncology leads with 28% share, driven by rising use of nanotechnology for targeted cancer therapy, reduced side effects, and improved drug efficiency. Anti-infective accounts for 18%, supported by increasing demand for advanced drug delivery systems to treat bacterial and viral infections. Anti-inflammatory / Immunology holds 17%, fueled by growing cases of autoimmune diseases and chronic inflammatory disorders. Cardiovascular / Physiology represents 15%, driven by need for precise drug delivery in heart-related conditions. Neurology accounts for 12%, supported by increasing research in brain-targeted drug delivery systems. Others contribute 10%, including metabolic and rare disease treatments.

By Region

North America - 38% Share
North America leads with 38%, driven by strong pharmaceutical research, high investment in nanotechnology, and presence of major biotech companies in the U.S. and Canada.

Europe - 25% Share
Europe holds 25%, supported by increasing clinical research, advanced healthcare systems, and strong government funding for nanomedicine across Germany, the U.K., France, and Switzerland.

Asia Pacific - 23% Share
Asia Pacific accounts for 23%, fueled by growing pharmaceutical manufacturing, rising healthcare spending, and increasing nanotechnology research in China, India, Japan, and South Korea.

Middle East & Africa - 7% Share
The Middle East & Africa represent 7%, driven by improving healthcare infrastructure and gradual adoption of advanced drug delivery technologies.

Latin America - 7% Share
Latin America holds 7%, supported by expanding pharmaceutical sector and increasing clinical research activities in Brazil, Mexico, and Argentina.

FAQ

What is the current size of the Nanotechnology in Drug Delivery Market?

A: In 2023, the Nanotechnology in Drug Delivery Market was valued at US$ 51.4 billion , reflecting its strong industry presence.

Q2: How large is the Nanotechnology in Drug Delivery Market expected to be by 2030?

A: By 2030, industry forecasts suggest the Nanotechnology in Drug Delivery Market will grow to around US$ 203.6 billion, demonstrating significant expansion.

Q3: What is the growth rate of the Nanotechnology in Drug Delivery Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 17.9% during the forecast period from 2024 to 2031.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.